DR. MARTENS PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 85.35 GBX | -0.52% |
|
-2.35% | -3.67% |
| Jun. 05 | Berenberg raises Taylor Wimpey to 'buy' | AN |
| Jun. 03 | Dr. Martens plc Announces Executive Changes | CI |
Valuation
| Fiscal Period: March | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 4,532 | 2,388 | 1,424 | 825.4 | - | - |
| Enterprise Value (EV) 1 | 4,706 | 2,554 | 1,712 | 844 | 1,167 | 1,172 |
| P/E ratio | 126 x | 13.2 x | 11 x | 12.5 x | 29 x | 14.6 x |
| Yield | - | 2.3% | 4.1% | 5.97% | 3.01% | 3.43% |
| Capitalization / Revenue | 5.86 x | 2.63 x | 1.42 x | 0.96 x | 0.98 x | 0.93 x |
| EV / Revenue | 6.09 x | 2.81 x | 1.71 x | 0.96 x | 1.39 x | 1.32 x |
| EV / EBITDA | 21 x | 9.71 x | 6.99 x | 4.27 x | 8.06 x | 6.06 x |
| EV / FCF | 27.7 x | 19.3 x | 66.1 x | 20.4 x | 15.3 x | 14 x |
| FCF Yield | 3.61% | 5.17% | 1.51% | 4.91% | 6.52% | 7.13% |
| Price to Book | 30.1 x | 7.3 x | 3.52 x | 2.1 x | 2.17 x | 2 x |
| Nbr of stocks (in thousands) | 1,000,000 | 1,000,111 | 1,000,770 | 961,972 | - | - |
| Reference price 2 | 4.532 | 2.388 | 1.423 | 0.8580 | 0.8580 | 0.8580 |
| Announcement Date | 6/17/21 | 6/1/22 | 6/1/23 | 5/30/24 | - | - |
1GBP in Million2GBP
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 672.2 | 773 | 908.3 | 1,000 | 877.1 | 838 | 890.5 |
| EBITDA 1 | - | 224.2 | 263 | 245 | 197.5 | 144.7 | 193.4 |
| EBIT 1 | - | 193 | 229.3 | 176.2 | 122.2 | 68.22 | 108.5 |
| Operating Margin | - | 24.97% | 25.24% | 17.61% | 13.93% | 8.14% | 12.18% |
| Earnings before Tax (EBT) 1 | - | 70.9 | 214.3 | 159.4 | 93 | 39.31 | 75.4 |
| Net income 1 | 74.8 | 35.7 | 181.2 | 128.9 | 69.2 | 28.71 | 55.03 |
| Net margin | 11.13% | 4.62% | 19.95% | 12.89% | 7.89% | 3.43% | 6.18% |
| EPS 2 | - | 0.0360 | 0.1810 | 0.1290 | 0.0700 | 0.0296 | 0.0587 |
| Free Cash Flow 1 | - | 169.8 | 132.1 | 25.9 | 56.47 | 76.1 | 83.5 |
| FCF margin | - | 21.97% | 14.54% | 2.59% | 6.36% | 9.08% | 9.38% |
| FCF Conversion (EBITDA) | - | 75.74% | 50.23% | 10.57% | 28.93% | 52.58% | 43.18% |
| FCF Conversion (Net income) | - | 475.63% | 72.9% | 20.09% | 81.87% | 265.03% | 151.75% |
| Dividend per Share 2 | - | - | 0.0550 | 0.0584 | 0.0512 | 0.0258 | 0.0295 |
| Announcement Date | 10/2/20 | 6/17/21 | 6/1/22 | 6/1/23 | 5/30/24 | - | - |
1GBP in Million2GBP
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: March | 2021 S2 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 | 2024 S1 | 2024 Q3 | 2024 Q4 | 2024 S2 |
|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 454.8 | 369.9 | 538.4 | 418.6 | 581.7 | 395.8 | 290 | 213 | 481.3 |
| EBITDA | - | 88.8 | - | 88.8 | - | 77.6 | - | - | 119.9 |
| EBIT | - | - | - | - | - | 40.3 | - | - | - |
| Operating Margin | - | - | - | - | - | 10.18% | - | - | - |
| Earnings before Tax (EBT) | - | - | - | - | - | 25.8 | - | - | - |
| Net income | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | 0.0190 | - | - | - |
| Dividend per Share | - | - | - | - | - | 0.0156 | - | - | - |
| Announcement Date | 6/17/21 | 12/9/21 | 6/1/22 | 11/24/22 | 6/1/23 | 11/30/23 | - | - | 5/30/24 |
1GBP in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | 174 | 166 | 288 | 325 | 342 | 346 |
| Net Cash position 1 | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | 0.7756 x | 0.6304 x | 1.177 x | 1.665 x | 2.362 x | 1.791 x |
| Free Cash Flow 1 | - | 170 | 132 | 25.9 | 56.5 | 76.1 | 83.5 |
| ROE (net income / shareholders' equity) | - | 105% | 75.8% | 35.2% | 17.2% | 7.94% | 16.2% |
| ROA (Net income/ Total Assets) | - | - | - | - | 6.49% | 3.02% | 5.39% |
| Assets 1 | - | - | - | - | 1,063 | 949.6 | 1,021 |
| Book Value Per Share 2 | - | 0.1500 | 0.3300 | 0.4000 | 0.4100 | 0.4000 | 0.4300 |
| Cash Flow per Share 2 | - | 0.1600 | 0.1800 | 0.0800 | 0.1300 | 0.1500 | 0.1600 |
| Capex 1 | - | 18.6 | 25 | 51.4 | 51 | 44.2 | 48.7 |
| Capex / Sales | - | 2.41% | 2.75% | 5.14% | 5.75% | 5.27% | 5.47% |
| Announcement Date | 10/2/20 | 6/17/21 | 6/1/22 | 6/1/23 | 5/30/24 | - | - |
1GBP in Million2GBP
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
0.858
GBP
Average target price
0.7686
GBP
Spread / Average Target
-10.42%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -3.67% | 1.06B | |
| +56.23% | 27.11B | |
| +18.78% | 11B | |
| +28.02% | 10.91B | |
| +16.89% | 10.84B | |
| +57.37% | 9.01B | |
| +21.52% | 3.37B | |
| +69.21% | 3.03B | |
| -9.15% | 2.43B | |
| -11.19% | 2.24B |
- Stock Market
- Equities
- DOCS Stock
- Financials Dr. Martens plc
